Abstract

BackgroundImage-guided surgery may improve surgical outcome for colorectal cancer patients. Here, we evaluated the feasibility of a pretargeting strategy for multimodal imaging in colorectal cancer using an anti-carcinoembryonic antigen (CEA) x anti-histamine-succinyl-glycine (HSG) bispecific antibody (TF2) in conjunction with the dual-labeled diHSG peptide (RDC018), using both a fluorophore for near-infrared fluorescence imaging and a chelator for radiolabeling.MethodsNude mice with subcutaneous (s.c) CEA-expressing LS174T human colonic tumors and CEA-negative control tumors were injected with TF2. After 16 h, different doses of 111In-labeled IMP-288 (non-fluorescent) or its fluorescent derivative RDC018 were administered to compare biodistributions. MicroSPECT/CT and near-infrared fluorescence imaging were performed 2 and 24 h after injection. Next, the biodistribution of the dual-labeled humanized anti-CEA IgG antibody [111In]In-DTPA-hMN-14-IRDye800CW (direct targeting) was compared with the biodistribution of 111In-RDC018 in mice with TF2-pretargeted tumors, using fluorescence imaging and gamma counting. Lastly, mice with intraperitoneal LS174T tumors underwent near-infrared fluorescence image-guided resection combined with pre- and post-resection microSPECT/CT imaging.Results111In-RDC018 showed specific tumor targeting in pretargeted CEA-positive tumors (21.9 ± 4.5 and 10.0 ± 4.7% injected activity per gram (mean ± SD %IA/g), at 2 and 24 hours post-injection (p.i.), respectively) and a biodistribution similar to 111In-IMP288. Both fluorescence and microSPECT/CT images confirmed preferential tumor accumulation. At post mortem dissection, intraperitoneal tumors were successfully identified and removed using pretargeting with TF2 and 111In-RDC018.ConclusionA pretargeted approach for multimodal image-guided resection of colorectal cancer in a preclinical xenograft model is feasible, enables preoperative SPECT/CT, and might facilitate intraoperative fluorescence imaging.

Highlights

  • Colorectal cancer is the third most common cause of cancer deaths in the Western world [1]

  • Uptake of 111In-RDC018 remained low in carcinoembryonic antigen (CEA)

  • RDC018 was significantly higher than the uptake of 111In-DOTA-Di-histamine-succinul-glycine hapten peptide (IMP-288) (0.13 ± 0 %IA/g and 0.07 ± 0 %IA/ g p < 0.001)

Read more

Summary

Introduction

Colorectal cancer is the third most common cause of cancer deaths in the Western world [1]. Overexpression of carcinoembryonic antigen (CEA) is present in 90–95% colorectal cancers [4, 5]. This biomarker may be targeted by the high-affinity monoclonal antibody hMN-14. HMN-14 labeled with Indium-111 (111In) and conjugated to IRDye800CW ([111In]In-DTPA-hMN-14-IRDye800CW) was shown to accumulate in CEA-expressing tumor xenografts and enabled radio- and fluorescence-guided surgery of colorectal tumor nodules [7]. Image-guided surgery may improve surgical outcome for colorectal cancer patients. We evaluated the feasibility of a pretargeting strategy for multimodal imaging in colorectal cancer using an anti-carcinoembryonic antigen (CEA) x anti-histamine-succinyl-glycine (HSG) bispecific antibody (TF2) in conjunction with the dual-labeled diHSG peptide (RDC018), using both a fluorophore for near-infrared fluorescence imaging and a chelator for radiolabeling

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call